drugset / Trial / NCT04456686

Chronic Pain Master Protocol (CPMP): A Study of LY3016859 in Participants With Osteoarthritis

NCT04456686

Phase 2 Completed 117 enrolled Eli Lilly and Company
RandomizedParallel-groupDouble-blindTreatment

Summary

This study is being done to test the safety and efficacy of LY3016859 for the treatment of osteoarthritis pain. This trial is part of the chronic pain master protocol H0P-MC-CPMP (NCT05986292) which is a protocol to accelerate the development of new treatments for chronic pain.

Timeline

Start
2020-07-01
Primary completion
2021-04-22
Completion
2021-08-26

Drugs

EvaluationDrugModalityDoseRoute
Subject Fepixnebart Monoclonal antibody 500 mg Intravenous

Indications